Company intelligence / Profile preview

Synergia Medical

Mont-Saint Guibert, Walloon Region, Belgiumsynergia-medical.com ↗

Ownership: Private
Employees: ~25
Development stage: Phase 1

Overview

The NAO.VNS™ device has been successfully implanted in five patients as part of the AURORA first-in-human study. The primary safety endpoint was met with strong safety results, robust device performance, and positive patient outcomes. All patients recovered fully and began stimulation therapy as planned. The company plans to advance into pivotal FDA and CE trials.

Therapeutic areas: Neurology
Modalities: Device (Neurostimulation device)Optoelectronic technology
Industry: Implantable Medical Devices

Drug pipeline

1 asset

NAO.VNS

Phase 1

Indications: Drug-resistant epilepsy, Chronic Pain, Depression, Parkinson's Disease, Sleep Apnoea

Partnerships

Wallonia Region funding partnerEuropean Union EIC program funding partner

Beyond the preview

Go deeper on Synergia Medical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Synergia Medical.

Explore the full profile